Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
Consulting agrmnt
|
|
Enliven Therapeutics, Inc. (IMRA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Lyssikatos Joseph P (Chief Scientific Officer) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Sold 12,000 shares
@ $13.6248, valued at
$163.5k
Exercised 12,000 options to buy
@ $1.12, valued at
$13.4k
|
|
| 09/29/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 09/28/2023 |
4
| 5AM Partners VI, LLC (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Sold 164,789 shares
@ $15, valued at
$2.5M
Sold 32,711 shares
@ $15, valued at
$490.7k
|
|
| 09/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Enliven Therapeutics, Inc. Selected Condensed Consolidated Financial Information Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 15,183 $ 7,937 $ 27,063 $ 14,996 General and administrative 4,951 1,079 9,489 2,698 Total operating expenses 20,134 9,016 36,552 17,694 Loss from operations Other income , net 3,413 127 5,107 136 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares outstanding, basic and diluted 40,961 3,104 29,862 2,991 Balance Sheets June 30, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and marketable securities $ 277,865 $ 75,536 Prepaid expenses and other current assets 5,310 2,217 Total current assets 283,175 77,753 Pr..." |
|
| 07/06/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/05/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/19/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Exercised 2,125 options to buy
@ $4.28, valued at
$9.1k
|
|
| 05/19/2023 |
4
| Gupta Rishi (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Exercised 2,125 options to buy
@ $4.28, valued at
$9.1k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
SC 13G
| FMR LLC reports a 10.7% stake in ENLIVEN THERAPEUTICS INC |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/24/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/21/2023 |
8-K/A
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/13/2023 |
SC 13G
| Venrock Healthcare Capital Partners III, L.P. reports a 5.4% stake in Enliven Therapeutics, Inc. |
| 03/06/2023 |
3
| 5AM Partners VI, LLC (10% Owner) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 03/06/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.6% stake in Enliven Therapeutics, Inc. |
| 03/06/2023 |
SC 13D
| 5AM Ventures VI, L.P. reports a 14.1% stake in Enliven Therapeutics, Inc. |
| 03/01/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/01/2023 |
8-K
| Acquisition/merger/asset purchase announced, Entered into consulting agreement|
Docs:
|
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation",
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation",
"Contingent Value Rights Agreement between the Company and Rights Agent",
"November 10, 2022",
"February 14, 2020",
"Rahul Ballal Separation Agreement",
"March 15, 2022",
"ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter",
"ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter",
"Contingent Value Rights Agreement between the Company and Rights Agent" |
|
| 02/28/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/28/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/27/2023 |
4
| Schwab Andrew J. (Director) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 4,838,092 shares
@ $0
Granted 960,383 shares
@ $0 |
|
| 02/27/2023 |
4
| Heyman Richard A. (Director) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 149,820 shares
@ $0
Granted 37,407 shares
@ $0
Granted 31,172 shares
@ $0
Granted 20,657 options to buy
@ $2.48, valued at
$51.2k
|
|
| 02/27/2023 |
3
| Heyman Richard A. (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
4
| Gupta Rishi (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 7,611,458 shares
@ $0
Granted 288,114 shares
@ $0 |
|
| 02/27/2023 |
4
| Bauer Jake (Director) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 87,372 shares
@ $0
Granted 17,706 options
@ $2.48, valued at
$43.9k
|
|
| 02/27/2023 |
3
| Schwab Andrew J. (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Phillips Andrew John (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Gupta Rishi (10% Owner) has filed a Form 3 on Enliven Therapeutics, Inc. |
|
|
|